Re: Reply to letter to the editor re: 'practical guide on the use of imiquimod cream to treat lentigo maligna'

Australas J Dermatol. 2022 May;63(2):e198-e199. doi: 10.1111/ajd.13797. Epub 2022 Feb 2.

Pascale Guitera^{1

2

3}, Andreanne Waddell⁴, Elizabeth Paton⁵, Gerald B Fogarty^{1

3

6}, Angela Hong^{1

3

6}, Richard A Scolyer^{1

3

7}, Jonathan R Stretch^{1

3}, Brett A O'Donnell⁸, Giovanni Pellacani⁹

¹ Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
² Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, Australia.
³ Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
⁴ Department of Medicine/Division of Dermatology, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
⁵ Melanoma and Skin Cancer Trials (MASC Trials), Monash University, Melbourne, Australia.
⁶ Genesis Cancer Care, North Sydney, Australia.
⁷ Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.
⁸ Departments of Ophthalmology, Royal North Shore Hospital, Sydney, Australia.
⁹ Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.

No abstract available

Keywords: Hutchinson's Melanotic Freckle; Imiquimod; Lentigo maligna; Multidisciplinary consensus; diagnosis; pathology; treatment..

Publication types